137 results
Page 3 of 7
8-K
EX-99.1
8vafyjmfd0o9p
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
nxfdenix852l5u7sa7ns
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
z97c 8pedo23p76n8
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-3.1
m7dj08mwwh
17 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-99.1
9ib7v wt1w2
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
sll1twanhs9nh 7t9
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
bxqjucls hpv4tnf8su
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
nao oqq03e
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
kwpu035gc0yco mkv
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
erexno
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
gqvdvy
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
1rv9wsz9 naai
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
j6x905
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am